Navigation Links
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
Date:11/1/2008

cluding HCV, HIV and tuberculosis."

About the Phase IIa Study

Investigators in five European countries assessed the antiviral activity, safety, and pharmacokinetics of two once-daily regimens of TMC435 (25 mg or 75 mg TMC435 versus placebo) in fifty HCV genotype 1 treatment-naive patients in an ongoing double-blind, placebo-controlled phase IIa trial. Patients were randomized to receive either seven days of monotherapy with TMC435 or placebo followed by 21 days of triple therapy with TMC435 or placebo, plus PegIFNalpha-2a (180 mcg once weekly) and RBV (1000-1200 mg daily); or, 28 days of triple therapy with TMC435 or placebo, plus PegIFNalpha-2a and RBV. After day 28, patients continue on PegIFNalpha-2a/RBV alone for a total of 24 or 48 weeks at the discretion of the investigator.

TMC435 data from other studies will also be presented at the AASLD Liver Meeting.

About HCV

According to the Centers for Disease Control and Prevention (CDC), about 3.2 million people in the United States are infected with chronic HCV and 19,000 people are newly infected each year.(4) Chronic infection with HCV can lead to cirrhosis and liver cancer, and is the most common cause of liver transplant in the United States.(4,5)

About Tibotec BVBA

Tibotec BVBA is a global pharmaceutical and research development company. The company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, Pa. and Cork, Ireland. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS and hepatitis C drugs, and anti-infectives for diseases of high unmet medical need.

Forward Looking Statement

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could var
'/>"/>

SOURCE Tibotec BVBA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
2. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
3. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Professional Compounding Centers of America (PCCA) ... the three best scientific presentations at the sixth ... The Formulating Better Medicines for Children  conference, ... Athens, Greece , includes dozens of poster-style ... which three winners will be selected by a ...
(Date:8/21/2014)... 2014   Royal Philips (NYSE: ... has received 510(k) clearance from the U.S. Food ... application for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through ... with pre-procedural, high-precision positioning to treat aortic stenosis ... is available as part of Philips IntelliSpace ...
(Date:8/21/2014)... 21, 2014  SI-BONE, Inc. ( San Jose, ... the use of the iFuse Implant System, ® ... of the sacroiliac (SI) joint, announced that Priority Health ... its Lumbar Fusion Medical Policy No. 91590-R4 providing positive ... policy states that the fusion procedure, which employs the ...
Breaking Medicine Technology:Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
(Date:8/21/2014)... August 21, 2014 The new ... from Lockton Companies and builds on Accountable Health ... cellular glucometer, combined with Accountable Health’s robust member ... analytic capabilities and adds a custom incentive platform ... eye exams, provider visits, HbA1c testing and more. ...
(Date:8/21/2014)... 21, 2014 Relias Learning, the leader ... and human services markets, announced the latest release of ... the Tin Can API. , “Supporting the Tin ... the most advanced mobile learning capabilities and the ability ... tools and techniques,” says Jim Triandiflou, CEO of Relias ...
(Date:8/21/2014)... to be elicited by T-type calcium channels in ... regulate influxes of calcium. These channels enable thalamic ... the neurons to enter a hyper-excited state. , ... firing and absence seizures, the researchers conducted an ... gene targeting techniques to delete the T-type calcium ...
(Date:8/21/2014)... August 21, 2014 ... Peripheral Vascular Devices Market by Angioplasty ... Catheter (IVUS, OCT), IVC Filter (Retrievable), ... 2018" analyzes and studies the major ... the U.S. and Canada. , Browse ...
(Date:8/21/2014)... mynt welcomes industry leaders Rob and ... its growing company. Since its pre-launch in April, mynt ... and continues to gain momentum leading up to its ... Tiffanie came into network marketing by chance. Tiffanie worked ... network marketing companies. Tiffanie needed help at one particular ...
Breaking Medicine News(10 mins):Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 2Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 3Health News:Relias Learning Announces Support for Tin Can API 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Industry Leaders Rob and Tiffanie Moffitt Join mynt 2
... for cancer when they were children have a higher-than-average ... severe in the years following treatment, according to ... of the International Society of Paediatric Oncology (SIOP) in ... Cancer Center and their colleagues say their findings suggest ...
... scientists will receive grants totaling $9.35 million to help ... and traumatic brain injury. The grants from the ... 21, to Dr. Henry Klassen, Leslie M. Thompson, Brian ... Sue and Bill Gross Stem Cell Research Center at ...
... cholesterol-lowering drug reduced the enlarged prostates of hamsters to the ... prostatic hyperplasia (BPH), report researchers at Children,s Hospital Boston and ... Urology. Together, the drugs worked even better. "We don,t ... lowering cholesterol has the potential to reduce BPH in men," ...
... WHAT: Researchers funded by the National Institutes of Health have ... is evolving into two separate species with different traits, ... and potentially require new disease prevention methods. Their findings ... issue of the journal Science . A. ...
... of California, San Diego School of Medicine indicates that parent-only ... that include parents and child, while at the same time ... The results were published today in the advanced online edition ... PhD, associate professor of pediatrics and psychiatry at UC San ...
... -- If you,re a nonsmoker who lives in an apartment, ... smoke, says a new study. Researchers at Roswell Park ... 30 apartments within 11 buildings and found that secondhand smoke ... apartments of nonsmokers. The extent of the secondhand smoke ...
Cached Medicine News:Health News:Childhood cancer survivors face long-term risk of GI complications, study finds 2Health News:UCI stem cell researchers to receive $9.35 million in state funding 2Health News:UCI stem cell researchers to receive $9.35 million in state funding 3Health News:Cholesterol-lowering drug shrinks enlarged prostates in hamster model 2Health News:Parent-only treatment may be equally effective for children who are obese 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: